A Case of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Refractory to Epirubicin That Showed Marked Decrease in Tumor Markers After Transcatheter Arterial Infusion with Miriplatin

Overview

Journal Case Rep Oncol

Publisher Karger

Specialty Oncology

Date 2011 Jul 9

PMID 21738504

Citations 4

Authors

Hiroki Nishikawa

Tadashi Inuzuka

Haruhiko Takeda

Jun Nakajima

Azusa Sakamoto

Sinichiro Henmi

Tetsurou Ishikawa

Sumio Saito

Ryuichi Kita

Toru Kimura

Yukio Osaki

Yorimitsu Koshikawa

Affiliations

Soon will be listed here.

Abstract

Miriplatin, a cisplatin derivative with a high affinity for iodized ethyl esters of fatty acids from poppy seed oil, is a novel chemotherapeutic agent designed for use in the transarterial treatment of hepatocellular carcinoma (HCC). Here, we describe transcatheter arterial infusion (TAI) using miriplatin to treat a case of advanced HCC with portal vein tumor thrombus (PVTT) refractory to TAI with epirubicin. A 66-year-old man with advanced hepatitis C virus-related HCC with PVTT in the right lobe of the liver was treated with TAI with epirubicin suspended in iodized oil; however, tumor marker levels (alpha-fetoprotein and des-gamma-carboxy protein) did not decrease. Next, he was treated twice with TAI with miriplatin suspended in iodized oil. The tumor marker levels markedly decreased to a nearly normal range and the size of the main tumor was markedly reduced according to dynamic computed tomography. No serious adverse events occurred during the course of treatment with TAI and miriplatin. Therefore, we suggest that TAI with miriplatin is a safe and effective treatment option for advanced HCCs refractory to TAI with epirubicin.

Citing Articles

Effect of double platinum agents, combination of miriplatin-transarterial oily chemoembolization and cisplatin-hepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two cases.

Ogawa K, Kamimura K, Watanabe Y, Motai Y, Kumaki D, Seki R World J Clin Cases. 2017; 5(6):238-246.

PMID: 28685137 PMC: 5480072. DOI: 10.12998/wjcc.v5.i6.238.

Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial.

Kamimura K, Suda T, Yokoo T, Kamimura H, Kanefuji T, Tsuchiya A BMC Cancer. 2017; 17(1):322.

PMID: 28490356 PMC: 5425991. DOI: 10.1186/s12885-017-3320-7.

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan.

Nishikawa H, Osaki Y, Kita R, Kimura T Cancers (Basel). 2013; 4(1):165-83.

PMID: 24213234 PMC: 3712670. DOI: 10.3390/cancers4010165.

Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma.

Kamimura K, Suda T, Tamura Y, Takamura M, Yokoo T, Igarashi M BMC Gastroenterol. 2012; 12:127.

PMID: 22994941 PMC: 3482551. DOI: 10.1186/1471-230X-12-127.

References

Ichikawa W, Togo S, Osanai T, Miyanaga T, Sawai S, Yamashita T . [Clinical study on the effect of intra-arterial injection of mitoxantrone-lipiodol emulsion for hepatocellular carcinoma]. Gan To Kagaku Ryoho. 1994; 21(13):2212-4. View

Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N . Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2008; 64(3):473-83. PMC: 2691803. DOI: 10.1007/s00280-008-0895-3. View

Kraybill W, Harrison M, Sasaki T, FLETCHER W . Regional intra-arterial infusion of adriamycin in the treatment of cancer. Surg Gynecol Obstet. 1977; 144(3):335-8. View

Maeda M, Uchida N, Sasaki T . Liposoluble platinum(II) complexes with antitumor activity. Jpn J Cancer Res. 1986; 77(6):523-5. View

Kishimoto S, Noguchi T, Yamaoka T, Fukushima S, Takeuchi Y . Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration. Biol Pharm Bull. 2000; 23(3):344-8. DOI: 10.1248/bpb.23.344. View

KINAMI Y, Miyazaki I . The superselective and the selective one shot methods for treating inoperable cancer of the liver. Cancer. 1978; 41(5):1720-7. DOI: 10.1002/1097-0142(197805)41:5<1720::aid-cncr2820410511>3.0.co;2-7. View

Takayasu K, Arii S, Matsuo N, Yoshikawa M, Ryu M, Takasaki K . Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol. 2000; 175(3):699-704. DOI: 10.2214/ajr.175.3.1750699. View

Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M . Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer. 1989; 64(8):1586-94. DOI: 10.1002/1097-0142(19891015)64:8<1586::aid-cncr2820640805>3.0.co;2-e. View

Leung W, Shiu W, Leung N, Chan M, Tao M, Li A . Treatment of inoperable hepatocellular carcinoma by intra-arterial lipiodol and 4'-epidoxorubicin. Cancer Chemother Pharmacol. 1992; 29(5):401-4. DOI: 10.1007/BF00686011. View

10.

Buchwald H, GRAGE T, Vassilopoulos P, Rohde T, VARCO R, Blackshear P . Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer. 1980; 45(5):866-9. DOI: 10.1002/1097-0142(19800301)45:5<866::aid-cncr2820450507>3.0.co;2-3. View

11.

Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I . Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res. 2010; 40(7):686-92. DOI: 10.1111/j.1872-034X.2010.00674.x. View

12.

Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T . Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. Cancer Sci. 2008; 100(1):189-94. PMC: 11159647. DOI: 10.1111/j.1349-7006.2008.01010.x. View

13.

Okusaka T, Okada S, Ueno H, Ikeda M, YOSHIMORI M, Shimada K . Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology. 2000; 58(4):293-9. DOI: 10.1159/000012115. View

14.

ANSFIELD F, Ramirez G, Davis Jr H, Wirtanen G, JOHNSON R, Bryan G . Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer. 1975; 36(6 Suppl):2413-7. DOI: 10.1002/1097-0142(197512)36:6<2413::aid-cncr2820360621>3.0.co;2-3. View